← Eichor
Condition: Glomerulopathy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Glomerulopathy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
Phase 2 · 6 location(s) · Omeros Corporation · NCT06209736A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
Phase 3 · 31 location(s) · Cerium Pharmaceuticals, Inc. · NCT05696613Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center
Phase N/A · 5 location(s) · University of Michigan · NCT01016613Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07010250NEPTUNE Match Study
NA · 16 location(s) · University of Michigan · NCT04571658Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Phase N/A · 1 location(s) · University of Michigan · NCT05505500Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Phase 3 · 87 location(s) · Novartis Pharmaceuticals · NCT04817618A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Phase 2 · 23 location(s) · Akebia Therapeutics · NCT07268638Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary
Phase 3 · 6 location(s) · Novartis Pharmaceuticals · NCT07498335Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Phase 2 · 47 location(s) · Travere Therapeutics, Inc. · NCT05003986Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Phase 3 · 9 location(s) · Novartis Pharmaceuticals · NCT05795140Home Reported Outcomes in C3G Study
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07029542Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
Phase 1 · 19 location(s) · Everest Medicines (China) Co.,Ltd. · NCT05800873Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Phase 3 · 21 location(s) · Novartis Pharmaceuticals · NCT06858319Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
Phase 2 · 4 location(s) · Region Skane · NCT04183101Atacicept in Multiple Glomerular Diseases
Phase 2 · 1 location(s) · Vera Therapeutics, Inc. · NCT06983028Chinese Adults With Kidney Disease
Phase 2 · 9 location(s) · ADARx Pharmaceuticals, Inc. · NCT07522099A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
Phase N/A · 3 location(s) · Novartis Pharmaceuticals · NCT07416162Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Phase 3 · 53 location(s) · Novartis Pharmaceuticals · NCT03955445Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Phase 2 · 2 location(s) · National Institute of Diabetes and Digestive and Kidney Dise · NCT00977977Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinur
Phase 2 · 2 location(s) · Everest Medicines (China) Co.,Ltd. · NCT07614477National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852Study of Ravulizumab in Pediatric Participants With Primary IgAN
Phase 3 · 15 location(s) · Alexion Pharmaceuticals, Inc. · NCT07024563Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulop
Phase 4 · 7 location(s) · NephroNet, Inc. · NCT07225387A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients Wit
Phase 1 · 16 location(s) · eleva GmbH · NCT07483827IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT02954419ASF Alport Patient Registry
Phase N/A · 1 location(s) · Alport Syndrome Foundation · NCT06526741Study of BHV-1400 in IgA Nephropathy
Phase 1 · 15 location(s) · Biohaven Therapeutics Ltd. · NCT07054684Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
Phase 4 · 1 location(s) · Chinese PLA General Hospital · NCT05839314KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Phase N/A · 6 location(s) · Seoul National University Hospital · NCT03929887
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.